Corvus Pharmaceuticals, Inc. (CRVS)
Automate Your Wheel Strategy on CRVS
With Tiblio's Option Bot, you can configure your own wheel strategy including CRVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRVS
- Rev/Share 0.0
- Book/Share 0.8664
- PB 24.631
- Debt/Equity 0.0141
- CurrentRatio 8.2913
- ROIC -0.5339
- MktCap 1593711746.0
- FreeCF/Share -0.389
- PFCF -49.4634
- PE -117.2617
- Debt/Assets 0.0126
- DivYield 0
- ROE -0.2578
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CRVS | Barclays | -- | Overweight | -- | $16 | Oct. 13, 2025 |
| Initiation | CRVS | H.C. Wainwright | -- | Buy | -- | $11 | Jan. 2, 2025 |
News
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Published: February 02, 2026 by: MarketBeat
Sentiment: Positive
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might obscure the fact that a number of individual companies have had a supercharged start to the year, dramatically outperforming the market benchmark.
Read More
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.
Read More
Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Does Corvus Pharmaceuticals (CRVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 25.3% in Corvus (CRVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Positive
Corvus Pharmaceuticals, Inc. reported highly positive phase 1 cohort 4 data for soquelitinib in moderate-to-severe atopic dermatitis. 75% of patients on 200 mg soquelitinib BID achieved EASI 75, with benefits persisting one month post-treatment. Longer treatment duration improved outcomes, including for patients previously treated with other therapies.
Read More
Soquelitinib Data Push Corvus Pharmaceuticals Stock Higher: What You Should Know
Published: January 21, 2026 by: Seeking Alpha
Sentiment: Positive
Corvus Pharmaceuticals, Inc. stock surged 165% on strong Phase 1 soquelitinib data in moderate-to-severe atopic dermatitis, including treatment-resistant patients. Soquelitinib achieved 75% EASI-75 and 33% IGA 0/1 rates, with favorable safety and biomarker evidence supporting its differentiated immunomodulatory mechanism. CRVS initiated a $150M equity offering to extend cash runway and fund pivotal Phase 2/3 trials, with durability of response as the next critical catalyst.
Read More
Corvus Stock Spikes On Heels Of Strong Eczema Study Results
Published: January 20, 2026 by: Benzinga
Sentiment: Positive
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) on Tuesday shared data from cohort 4 of the Phase 1 trial evaluating soquelitinib in patients with moderate-to-severe atopic dermatitis.
Read More
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025
Published: October 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1)
Read More
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Leiv Lea - Chief Financial Officer Richard A. Miller - Co-Founder, President, CEO & Chairman of the Board Conference Call Participants Aydin Huseynov - Ladenburg Thalmann & Co. Inc., Research Division Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Zack Kubow - Real Chemistry, Inc. Operator Good afternoon, everyone.
Read More
3 Penny Stocks Wall Street Sees With 243% Upside
Published: June 11, 2025 by: 24/7 Wall Street
Sentiment: Positive
“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
Read More
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, Investor Relations Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Securities Li Watsek - Cantor Jeff Jones - Oppenheimer Roger Song - Jefferies Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
Read More
Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Positive
Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments.
Read More
Corvus Pharmaceuticals: Now At Cruising Altitude
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Positive
Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising developments, including a Phase 2 trial for autoimmune lymphoproliferative syndrome and potential solid tumor trials, but current data is inconclusive. Significant shareholder activity, including warrant exercises, has impacted stock price and ownership dynamics, with potential future dilution if more shares are issued.
Read More
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conference Call Participants Jeff Jones - Oppenheimer Aydin Huseynov - Ladenburg Thalmann Cha Cha Yang - Jefferies Daniel Bronder - Cantor Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.
Read More
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum
Read More
About Corvus Pharmaceuticals, Inc. (CRVS)
- IPO Date 2016-03-23
- Website https://www.corvuspharma.com
- Industry Biotechnology
- CEO Richard A. Miller
- Employees 31